BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30611606)

  • 1. A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapy.
    Rinscheid A; Lee J; Kletting P; Beer AJ; Glatting G
    Z Med Phys; 2019 Dec; 29(4):314-325. PubMed ID: 30611606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in
    Rinscheid A; Kletting P; Eiber M; Beer AJ; Glatting G
    Med Phys; 2019 Dec; 46(12):5861-5866. PubMed ID: 31587333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of sampling schedules on [
    Rinscheid A; Kletting P; Eiber M; Beer AJ; Glatting G
    EJNMMI Phys; 2020 Jun; 7(1):41. PubMed ID: 32556844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model.
    Hardiansyah D; Riana A; Beer AJ; Glatting G
    Z Med Phys; 2023 Feb; 33(1):70-81. PubMed ID: 35961809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise model.
    Hardiansyah D; Guo W; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
    Nuklearmedizin; 2017 Feb; 56(1):23-30. PubMed ID: 27885372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise.
    Hardiansyah D; Guo W; Kletting P; Mottaghy FM; Glatting G
    Med Phys; 2016 Sep; 43(9):5145. PubMed ID: 27587044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule.
    Maaß C; Sachs JP; Hardiansyah D; Mottaghy FM; Kletting P; Glatting G
    EJNMMI Res; 2016 Dec; 6(1):30. PubMed ID: 27015662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model.
    Hardiansyah D; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
    Phys Med; 2017 Oct; 42():298-304. PubMed ID: 28739143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for
    Peterson AB; Mirando DM; Dewaraja YK
    EJNMMI Res; 2023 Jun; 13(1):57. PubMed ID: 37306783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT in clinical patients and realistic simulations.
    Peterson AB; Mirando DM; Dewaraja YK
    Res Sq; 2023 Apr; ():. PubMed ID: 37131738
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of patient-based treatment planning in peptide receptor radionuclide therapy.
    Hardiansyah D; Maass C; Attarwala AA; Müller B; Kletting P; Mottaghy FM; Glatting G
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):871-880. PubMed ID: 26577941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a
    Zhao W; Esquinas PL; Frezza A; Hou X; Beauregard JM; Celler A
    Phys Med Biol; 2019 Aug; 64(17):175006. PubMed ID: 31287093
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.
    Kletting P; Kull T; Maaß C; Malik N; Luster M; Beer AJ; Glatting G
    J Nucl Med; 2016 Apr; 57(4):503-8. PubMed ID: 26678617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NUKDOS software for treatment planning in molecular radiotherapy.
    Kletting P; Schimmel S; Hänscheid H; Luster M; Fernández M; Nosske D; Lassmann M; Glatting G
    Z Med Phys; 2015 Sep; 25(3):264-74. PubMed ID: 25791740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy.
    Hardiansyah D; Begum NJ; Kletting P; Mottaghy FM; Glatting G
    Cancer Biother Radiopharm; 2016 Aug; 31(6):217-24. PubMed ID: 27403777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dosimetry procedure for organs-at-risk in
    Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P
    Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo Biokinetics of
    Beykan S; Fani M; Jensen SB; Nicolas G; Wild D; Kaufmann J; Lassmann M
    Contrast Media Mol Imaging; 2019; 2019():6438196. PubMed ID: 30733648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized kidney dosimetry in
    Hou X; Zhao W; Beauregard JM; Celler A
    Phys Med Biol; 2019 Aug; 64(17):175004. PubMed ID: 31456584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A five-compartment biokinetic model for
    Jeremic MZ; Matovic MD; Krstic DZ; Pantovic SB; Nikezic DR
    Med Phys; 2018 Dec; 45(12):5577-5585. PubMed ID: 30291717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of interpatient variability on organ dose estimates according to MIRD schema: Uncertainty and variance-based sensitivity analysis.
    Zvereva A; Kamp F; Schlattl H; Zankl M; Parodi K
    Med Phys; 2018 Jul; 45(7):3391-3403. PubMed ID: 29772064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.